Vienna, June 14, 2023 - The COVID-19 pandemic demonstrated the critical importance of resilient global supply chains. As the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA), we underscore the essential role of the off-patent pharmaceutical sector in ensuring that patients worldwide have equitable access to quality-assured, and affordable medicines.
IGBA is pleased to share key comments and proposals on selected provisions of the Zero Draft of the Pandemic Accord
The criticality of supply chain resilience has become increasingly apparent in recent years, including for essential medicines and health products. The COVID-19 pandemic and geopolitical tensions have highlighted certain vulnerabilities of global supply chains, particularly in the areas of raw materials, manufacturing, transportation, and logistics. Early in COVID 19 pandemic, widespread disruption of global trade created challenges for the uninterrupted supply of essential medicines, underscoring the importance of uniform support for resilient global supply chains.
- IGBA nominated David Gaugh, AAM's Interim CEO, as the new IGBA Chair for 2023 (April 2023)
- IGBA’s 25th Annual Conference highlights the true value of the off-patent medicines industry for patients and health systems around the world (February 2023)
- Jonathan Kimball takes over the position of IGBA Chair (January 2023)
- IGBA taking action to tackle shortages of antibiotic medicines (December 2022)
